Jason Hoitt
Corporate Officer/Principal presso STOKE THERAPEUTICS, INC.
Posizioni attive di Jason Hoitt
Società | Posizione | Inizio | Fine |
---|---|---|---|
STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | 15/04/2024 | - |
Storia della carriera di Jason Hoitt
Precedenti posizioni note di Jason Hoitt
Società | Posizione | Inizio | Fine |
---|---|---|---|
PROVENTION BIO, INC. | Corporate Officer/Principal | 01/06/2020 | 01/06/2023 |
DOVA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 16/12/2018 | 12/11/2019 |
INSMED INCORPORATED | Vendite & Marketing | 01/05/2017 | - |
SAREPTA THERAPEUTICS, INC. | Vendite & Marketing | 01/01/2013 | 01/05/2017 |
Formazione di Jason Hoitt
College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Posizioni
Corporate Officer/Principal | 3 |
Sales & Marketing | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 6 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
INSMED INCORPORATED | Health Technology |
SAREPTA THERAPEUTICS, INC. | Health Technology |
STOKE THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Provention Bio, Inc.
Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
- Borsa valori
- Insiders
- Jason Hoitt
- Esperienza